inflammatory disease

Ayaka Sugiura and Jeff Rathmell, PhD, are studying a metabolic enzyme involved in T cell function that may offer a new target for anti-inflammatory therapeutics.
November 11, 2021

CRISPR screen identifies new anti-inflammatory drug target

A novel CRISPR screen developed by Vanderbilt researchers identified a promising new target for anti-inflammatory therapeutics.

By Leigh MacMillan
Allison Norlander, PhD, R. Stokes Peebles, MD, and colleagues are studying an approved drug that enhances immune cells and might be useful for treating inflammatory and autoimmune diseases.
March 25, 2021

Team studies new use for pulmonary hypertension drug

An FDA-approved medication enhances the function of T regulatory cells (Treg), a class of immune cells that restrains the immune response, Vanderbilt investigators have discovered.

By Leigh MacMillan
July 13, 2020

“Nur” target may aid arthritis treatment

Vanderbilt immunologists have discovered that the protein Nur77 is part of a control mechanism that guards against autoimmunity in natural killer T cells.

By Bill Snyder
The organ-on-a-chip device used by Osteen’s lab allows a constant flow of fluids that more accurately represents human internal organ systems.
September 19, 2019

Study seeks factors that increase risk of toxicant exposure

Vanderbilt researchers hope to identify factors that may make humans more susceptible to toxicant exposure — specifically the presence of pre-existing inflammatory disease.

By Kelsey Herbers